# Accro Bioscience (Suzhou) Limited: Phase 1 study completed, 4 enrolled (Acute Graft-versus-Host Disease)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Accro Bioscience (Suzhou) Limited |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD. |
| NCT ID | NCT07070674 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Acute Graft-versus-Host Disease |
| Intervention types | drug |
| Target enrollment | 4 |
| Site countries | China |
| Posted | 2025-07-17 |
| Planned start | 2024-07-25 |
| Event | Completed |
| Event date | 2026-09-28 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07070674). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.